Huihe Medical Completes Nearly RMB 100 Million Series A Funding Round and Develops China's First Transvascular Tricuspid Valve Interventional Repair System

HuiHe Healthcare Officially Announces Completion of Nearly RMB 100 Million in Series A FinancingRecently, HuiHe Healthcare officially announced the completion of its Series A financing round, raising nearly RMB 100 million. The round was led by BioTrack Capital, with participation from SDIC Chuanghe, Guofang Capital, and existing shareholder Oriza Holdings. China Renaissance served as the exclusive financial advisor for this financing round.

HuiHe Healthcare, established in 2019, specializes in the research, development, and manufacturing of interventional medical devices for structural heart disease. The company possesses China’s first independently developed transcatheter tricuspid valve intervention repair system. Previously, the company completed a tens-of-millions-yuan angel financing round invested by Oriza Holdings. Following this Series A financing, the company will continue to advance the ongoing R&D and clinical approval of its tricuspid valve interventional products, as well as the development of other product pipelines related to structural heart disease.

The Company's Core Product: K-Clip^TM (Transcatheter Tricuspid Valve Repair System) Targeting tricuspid regurgitation, a common structural heart disease that is frequently secondary to left-sided heart valve pathologies (mitral or aortic valve), the condition affects a large population. In China, the prevalent number of patients with tricuspid regurgitation exceeds 1 million, with over 200,000 new cases of moderate-to-severe tricuspid regurgitation diagnosed annually. Without treatment, the disease progresses to heart failure; following the first episode of heart failure, the five-year mortality rate exceeds 50%, and overall survival typically does not exceed 10 years. Most existing patients with tricuspid regurgitation have previously undergone open-heart surgery for left-sided valve diseases, yet they often experience progressive development to severe tricuspid regurgitation postoperatively. The mortality rate associated with redo sternotomy for tricuspid valve intervention is as high as 30%.

Currently, the treatment of tricuspid regurgitation primarily relies on open-heart surgery, with repair being the preferred approach (>95%) and replacement considered only when repair is not feasible (<5%). However, due to the complexity of surgical procedures, high operational risks, and significant trauma to patients, the number of surgeries performed remains very low, leaving more than 100,000 patients untreated annually. Consequently, transcatheter repair for tricuspid regurgitation has gained recommendation from global guideline consensuses. Without exception, companies in the global structural heart disease sector are engaged in the research, development, or acquisition of transcatheter tricuspid valve repair products. In China, no such products have yet entered clinical trials, with HuiHe Healthcare’s K-Clip being the most advanced candidate. Meanwhile, HuiHe Healthcare has also developed its own innovative transcatheter mitral valve repair solution.

Lin Lin, Founder of HuiHe Healthcarestated: “The Kay’s procedure adopted by K-Clip is backed by decades of experience in cardiac surgery and evidence-based medicine, enabling complete replication of the surgical technique while reducing patient risk. We remain committed to original innovation, having undertaken numerous novel initiatives across all product components and the entire surgical workflow. This round of financing will significantly advance the continued R&D and clinical approval of our tricuspid valve intervention products, as well as the development of other product pipelines for structural heart disease.”

Wu An'an, Senior Investment Manager at BioTrack CapitalBioTrack Capital stated: "We are delighted to serve as the lead investor in HuiHe Healthcare's Series A financing round. Traditional surgical interventions for tricuspid valve disease are associated with significant trauma, high operative risk, frequent complications, and slow postoperative recovery. While there is substantial demand among physicians for new products, there is a global shortage of innovative interventional solutions that closely meet clinical needs. HuiHe Healthcare’s development of a transcatheter tricuspid valve repair system effectively addresses this gap. The market for interventional tricuspid valve repair holds immense potential both domestically and internationally, and remains a blue ocean sector in China. As a domestic pioneer, HuiHe Healthcare benefits from strong capabilities in continuous product development, leading us to maintain a long-term positive outlook on the company’s future growth. BioTrack Capital is honored to partner with HuiHe Healthcare, an industry leader. Together, we aim to build a leading enterprise in structural heart disease in China while contributing to the prevention and treatment of cardiovascular diseases nationwide."

Yang Zhiwen, Partner at Oriza HoldingsStatement: As an existing shareholder, during our year-plus journey with HuiHe Healthcare, we have witnessed the team’s iterative innovation capability, characterized by continuous self-disruption and repeated self-transcendence. While completing the development of its transcatheter tricuspid valve repair product, HuiHe Healthcare also developed interventional products for mitral regurgitation, becoming a company with comprehensive solutions for both mitral and tricuspid valves. We are optimistic about the future of HuiHe Healthcare and believe it will undoubtedly become a leading enterprise in the field of interventional heart valve repair. Therefore, we are participating in this follow-on investment in HuiHe as an existing shareholder.

Zhou Xiang, Head of the Financial Advisory Division at China Renaissance“Interventional innovative devices for structural heart disease are a key area we continue to closely monitor. The Chinese market for transcatheter tricuspid valve repair remains untapped. HuiHe Healthcare, committed to independent innovation, is the leading enterprise in this niche sector. China Renaissance is honored to have continuously served HuiHe Healthcare and believes that the company will emerge as a leading platform-based enterprise for interventional devices in structural heart disease in China.”